newsfilter
← Latest News
GlobeNewswire·

Albireo to Participate in Guggenheim Nantucket Therapeutics Conference

BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Guggenheim Therapeutics Confer